Niki BioSolutions, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Niki BioSolutions, Inc.'s latest filing, so interest coverage cannot be calculated.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Niki BioSolutions, Inc.'s return on equity of -5.94%, is lower than 15.00%, indicating bad performance

Niki BioSolutions, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Niki BioSolutions, Inc. has insufficient public price history to evaluate earnings stability.

Niki BioSolutions, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Niki BioSolutions, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Niki BioSolutions, Inc.'s yearly earnings has increased -68.06% since last year from $-4.27M to $-1.36M, signaling increasing performance

Niki BioSolutions, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -2.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Niki BioSolutions, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Niki BioSolutions, Inc. has insufficient public price history to evaluate revenue consistency.

Niki BioSolutions, Inc. has insufficient public price history to evaluate ROE consistency.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Niki BioSolutions, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Niki BioSolutions, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Niki BioSolutions, Inc. has a price-to-book ratio of 0.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Niki BioSolutions, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue